Leuko Revenue and Competitors
Estimated Revenue & Valuation
- Leuko's estimated annual revenue is currently $4.5M per year.
- Leuko's estimated revenue per employee is $251,000
Employee Data
- Leuko has 18 Employees.
- Leuko grew their employee count by 6% last year.
Leuko's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Cofounder & CTO | Reveal Email/Phone |
2 | Co-Founder and CEO | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | Hardware Engineer | Reveal Email/Phone |
5 | Product Software Engineer | Reveal Email/Phone |
6 | Deep Learning Engineering | Reveal Email/Phone |
Leuko Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $9.8M | 39 | 3% | N/A | N/A |
#2 | $8.5M | 34 | 3% | N/A | N/A |
#3 | $3M | 12 | -29% | N/A | N/A |
#4 | $5630M | 7477 | -11% | $450M | N/A |
#5 | $4.5M | 18 | 6% | N/A | N/A |
#6 | $7.2M | 57 | 27% | $29.6M | N/A |
#7 | $14.3M | 57 | -12% | N/A | N/A |
#8 | $2.3M | 18 | 6% | $44M | N/A |
#9 | $40.7M | 162 | -1% | N/A | N/A |
#10 | $45.7M | 182 | -5% | N/A | N/A |
What Is Leuko?
Leuko is developing the first non-invasive white blood cell device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel, blood draws and laboratory infrastructure. Based on MIT research, Leuko is re-imagining the way to perform these tests without extracting blood and in a portable device.
keywords:N/A
N/A
Total Funding
18
Number of Employees
$4.5M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Leuko News
Another company Leuko, based in Spain, is targeting cancer patients with a device that claims to be the first device for non-invasive white...
Another company Leuko, based in Spain, is targeting cancer patients with a device that claims to be the first device for non-invasive white...
... GlaxoSmithKline, Guardant Health, Leuko, Lilly, Medica Scientia Innovation Research, Menarini, Merck Sharp & Dohme, Nektar Therapeutics,...
... GlaxoSmithKline, Guardant Health, Leuko, Lilly, Medica Scientia Innovation Research, Menarini, Merck Sharp & Dohme, Nektar Therapeutics,...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.1M | 18 | -22% | $13M |
#2 | $1.5M | 18 | -36% | N/A |
#3 | $0.5M | 18 | -5% | $9.5M |
#4 | $2.2M | 18 | -5% | N/A |
#5 | $0.6M | 18 | 0% | $4.7M |